ASCO 2017 | Investigating alternative treatments for non-reponsive lymphoma patients

Mathias Rummel • 20 Jun 2017

ASCO 2017

Mantle Cell Lymphoma Non-Hodgkin Lymphoma

Mathias Rummel, MD, PhD from Justus Liebig University, Giessen, Germany discusses further improvements that can be made to treatments for patients with indolent and mantle cell lymphoma, to improve patient outcome. Currently, there is a small percentage of patients who don’t respond to first-line treatment, and it is crucial to develop and effective second-line treatment for these individuals. This improvement may occur as a result of maintenance therapy or a new type of treatment altogether. This demonstrates that it is important to continually investigate new and enhanced therapies that improve quality of life for current patients and provide alternatives for patients who may not respond. Recorded at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL.